Screener
Indivior Pharmaceuticals, Inc. INDV Accrued legal and settlement expenses
Accrued legal and settlement expenses at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept indv:IncreaseDecreaseInEstimatedLitigationLiability.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
FAQ
- What is Indivior Pharmaceuticals, Inc.'s accrued legal and settlement expenses?
- Indivior Pharmaceuticals, Inc. (INDV) reported accrued legal and settlement expenses of -$38M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s accrued legal and settlement expenses changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s accrued legal and settlement expenses increased by 38.7% year-over-year, from -$62M to -$38M.
- What does accrued legal and settlement expenses mean?
- This represents the net change in accruals for legal settlements, regulatory fines, or ongoing litigation-related liabilities during the reporting period. It serves as a critical indicator of potential legal exposure and the financial impact of resolving disputes or compliance issues. Tracking this helps investors understand the volatility of cash flows caused by non-recurring legal obligations and the company's overall risk profile.
Ask your AI about Indivior Pharmaceuticals, Inc.'s accrued legal and settlement expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude